

Review Article

Respiratory Diseases in Women

MeiLan K. Han^a, Michal Shteinberg^b, Deborah Assayag^c, Florence Schleich^d, Martino Pengo^{e,f},
Victoria M. Scicluna^a, Carolina Lombardi^{e,f}, Miriam Barrecheguren^{g,h,*}, Luis Jara-Palomares^{i,h}

^a University of Michigan, Ann Arbor, MI, USA

^b Pulmonology Institute and Cystic Fibrosis Center, Carmel Medical Center and the Technion-Israel Institute of Technology, the B. Rappaport Faculty of Medicine, Haifa, Israel

^c Department of Medicine, McGill University, Montreal, Canada

^d University of Liege, Belgium, GIGA I3, Respiratory Medicine CHU of Liege, Belgium

^e Istituto Auxologico Italiano IRCCS, Milan, Italy

^f Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

^g Vall d'Hebron Hospital, Barcelona, Spain

^h CIBERES, Carlos III Health Institute, Madrid, Spain

ⁱ Respiratory Department, Virgen del Rocío Hospital and Instituto de Biomedicina, Sevilla, Spain

ARTICLE INFO

Article history:

Received 10 April 2024

Accepted 24 October 2024

Available online 2 November 2024

Keywords:

Women

Respiratory diseases

COPD

ILD

Asthma

Vascular diseases

Bronchiectasis

Sex

Female

ABSTRACT

Respiratory diseases exhibit diverse patterns in prevalence, clinical presentations, and outcomes between men and women. Historically, certain conditions were more prevalent in men, but trends have shifted, highlighting the need to understand sex disparities in respiratory health. Social, environmental, and healthcare changes have reshaped the landscape of respiratory diseases, complicating diagnosis and treatment. Moreover, the underrepresentation of women in clinical trials has limited our understanding of their specific needs. In this review, we explore the sex differences in the prevalence, clinical characteristics, and presentation of respiratory diseases, emphasizing the importance of tailored approaches to diagnosis and management. By recognizing and addressing these disparities, we can advance toward more equitable and effective respiratory healthcare for all individuals.

© 2024 SEPAR. Published by Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Introduction

Several respiratory diseases occur predominantly in women, while other conditions that were almost exclusively found or more prevalent in men, have increased among women in the last several decades. Some diseases may also affect women differently and present with greater symptoms and/or severity than in men. Sex plays a relevant role in the development, prevalence and manifestations of the disease, but also in response to treatment. Changes in social roles, exposures and approach to illness have modified the nature and outcomes of some diseases. As up until more recently, women have had a smaller presence or have been completely excluded from randomized clinical trials, we have historically lacked data in this population.¹ In this review, we aim to

evaluate the sex differences in prevalence, clinical presentation and characteristics for some of the most frequent respiratory diseases.

Chronic Obstructive Pulmonary Disease (COPD) in Women

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide, affecting women at rates that are becoming comparable to men.^{2–6} However, women are developing COPD at younger ages and with less tobacco exposure.^{7,8} They also report more dyspnea and have higher incidence of exacerbations as compared to men with similar airflow limitations.⁹ In addition, women have not experienced the same improvements in mortality as men in recent years.^{3–6} Given these inequalities, it is crucial to work toward earlier diagnosis and optimized treatment among female patients.¹⁰

COPD is known to be underdiagnosed in women.¹¹ There are likely many contributors including differences in exposures, symptom presentation variance (less coughing and phlegm, but more

* Corresponding author.

E-mail address: miriam.barrecheguren@vallhebron.cat (M. Barrecheguren).

dyspnea and anxiety/depression), and issues with spirometry-based diagnosis.^{6,9,11} Women are slightly more likely to have preserved ratio impaired spirometry (PRISm; defined as $FEV_1 < 80\%$ predicted and $FEV_1/FVC \geq 0.7$).¹² Despite patients with PRISm having higher rates of development of COPD, and higher all-cause and respiratory mortality, optimal management for these patients remains unknown.¹² It is therefore important to continue to study these precursor conditions that provide a window of opportunity to facilitate earlier preventative and therapeutic measures.

When women are ultimately diagnosed with COPD, ensuring appropriate treatment is essential to mitigate their increased risk for exacerbations. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) committee recently updated its guidelines in 2023.¹³ One major change was a shift in nomenclature from the ABCD group classification to ABE, where group E are patients at increased risk for exacerbations, regardless of symptoms. The first line of treatment for Group E is now long-acting beta-agonist (LABA) + long-acting muscarinic antagonist (LAMA), with consideration for triple therapy (LABA + LAMA + inhaled corticosteroid [ICS]) if absolute blood eosinophils ≥ 300 cells/ μ L. This latter recommendation comes after 2 trials, IMPACT and ETHOS, demonstrated lower rates of COPD exacerbations with triple therapy as compared to LAMA/LABA.^{14,15} Other promising advances include use of biologic therapies for COPD with type II inflammation. In a recent trial, dupilumab was found to be associated with fewer exacerbations, as well as better quality of life and lung function than placebo.¹⁶ This is particularly salient for our female patients who have higher rates of asthma/COPD overlap than males.¹⁷

While there remain many challenges to optimizing care for women with COPD, there have been important advances. We have begun to understand COPD as a continuous spectrum of disease which may facilitate earlier detection. In addition, there have been important changes to therapeutic recommendations which have the potential to improve outcomes for patients with COPD, but particularly women.

Asthma in Women

Asthma is a heterogeneous disease of the airways^{18,19} and gender differences have been observed in prevalence, inflammatory phenotypes and asthma severity. During childhood, asthma prevalence is lower in females, while as adults, women have an increased prevalence and severity of asthma. Cluster analysis revealed differences according to sex with a women predominance in less atopic or in more symptomatic obese patients.^{20,21} Other studies found a reduced proportion of women in severe eosinophilic asthma associated with nasal polyps.²²

Different factors could explain these sex differences. Women are exposed to several hormonal changes with fluctuations of estrogen and progesterone levels during menstrual cycle, pregnancy and menopause. It has been reported that one fifth to one third of women have an increase in asthma symptoms during the pre-menstrual period associated with a decrease in lung function^{23,24} and an increased in type-2 markers such as sputum eosinophil counts and FeNO (fractional exhaled nitric oxide).²⁵ Progesterone has been shown to inhibit cilia beat frequency when activating its receptor expressed on the surface of airway epithelial cells. Moreover, estrogen receptor (ER)- α activation was associated with an increased bronchial hyperresponsiveness (BHR), IL-33, type-2 cytokines, and airway eosinophilic inflammation. Through ER- β ,^{26,27} estrogen has however been shown to reduce BHR and eosinophilic inflammation.

During pregnancy, changes in asthma symptom control were observed in a small proportion of women.²⁸ Women with more severe asthma prior to pregnancy seem at higher risk of

worsening.²⁹ Finally, some authors have proposed a “menopause-associated onset of asthma” phenotype, but this population has a higher prevalence of comorbidities such as obesity, anxiety and depression, and sometimes treatment with hormone replacement therapy (HRT). An increased risk of asthma has been reported in women receiving HRT, in a dose-dependent manner, especially in low BMI patients.³⁰ Hormonal contraceptive use, which prevents the harmful effect of fluctuations in estrogen and progesterone levels, has also been associated with a reduction in asthma incidence and a better symptom control. On the other hand, increased serum testosterone levels have been associated with decreased asthma prevalence in a dose-dependent manner and was associated with increase in lung function.³¹

Several studies have also highlighted sex specific single nucleotide polymorphisms in genes^{32,33} involved in immune pathways such as mediated by thymic stromal lymphopoietin (TSLP). Interesting studies also determined that DNA methylation due to environmental exposures and sex hormones are linked to asthma susceptibility.³⁴ Last but not least, women have a higher prevalence of hair product-related allergy and are more likely to have asthma symptoms when exposed to inorganic dusts.³⁵ There could also be differences in physical activity and eating habits between men and women.

In conclusion, data in the literature support the role of sex hormones on asthma incidence and severity. The underlying mechanisms and the different effect of hormones fluctuations and relationship with environmental exposures on asthma risk and symptoms control remains however unclear.

Women and Interstitial Lung Diseases

Sex impacts diagnosis, risk factors and management of interstitial lung diseases (ILD) in different ways. Epidemiological studies of idiopathic pulmonary fibrosis (IPF) have consistently shown a predominance of men, with only 20–45% of patients with IPF being female, although this varies across studies.^{36–41} In contrast, women are more likely to have autoimmune rheumatologic diseases, and therefore autoimmune-related ILD is also more common in women.^{42,43} One specific ILD diagnosis, lymphangioleiomyomatosis (LAM), a cystic lung disease, occurs almost exclusively in women. Such diagnostic differences across ILD may be due to biological factors, or to environmental factors. Sex hormones are postulated to play a role in sex-based differences noted in animal models of ILD, whereby estrogen seems to impact immune reactivity and inflammatory response leading to a protective effect of on disease severity, while male hormones exacerbate the fibrotic response.^{44–46} Estrogens are believed to play a pathogenic role in LAM since it is restricted almost exclusively to women, is exacerbated by exogenous estrogen use including oral contraceptives, worsens with the onset of menses,⁴⁷ and pregnancy.^{48–50} Genetic studies of familial ILD led to the discovery of mutations in genes involved in telomere homeostasis.⁵¹ In vitro, androgens and estradiol both seem to have an effect on telomerase activity.⁵² Among patients with telomere gene mutations, men are younger than women at ILD diagnosis,⁵³ and their telomere lengths are significantly shorter, suggesting that women are protected from telomere shortening, which is itself a risk factor for ILD.⁵⁴

In addition, ILD can also be impacted by several sex and sex-related factors (variables that differ between men and women)^{55,56} such as smoking⁵⁷ occupation/employment, exposures, and socioeconomic status. Smoking is strongly associated with an increased risk of IPF, particularly with a greater than 20 pack year smoking history.^{58,59} Occupational exposures to asbestos, silica, and mixed dusts, vapors, gases and fumes are less common in women, due to gendered exposures whereby women are less present in indus-

trial and labor workforces, leading to a predominance of men with pneumoconiosis.^{60–63}

Female sex has been shown in multiple observational studies to be a favorable prognostic factor for disease progression and survival in IPF and other ILD, including autoimmune related ILD.^{64–66} Sex is a key prognostic marker that has been incorporated into routinely used prognostic scores for ILD, such as the Gender, Age, Physiology (GAP) score.^{67–69} In a German administrative-data study, women with ILD also had lower hazard of respiratory and all-cause hospitalizations compared to men.⁷⁰

Although the benefits of ILD treatment does not differ between men and women, management of ILD has been shown to be unequal in women, compared to men. A large American study using medication insurance administrative databases has shown significant disparities in antifibrotic prescriptions for IPF between men and women, whereby men were more likely to receive antifibrotic medications compared to women (30% vs. 22%).⁷¹ In an observational study evaluating treatment initiation of patients with ILD across 3 distinct prospective cohorts, women in Canada started ILD-related medications later following diagnosis compared to men, especially in those with a diagnosis of IPF, after adjusting for disease severity.⁷² This was not seen in the other cohorts. A 236-patient study from France has shown that women with IPF were much less frequently referred for lung transplant compared to men.⁷³

Obstructive Sleep Apnoea (OSA) in Women

Sleep apnoea, characterized by reduction in airflow (hypopnea), and cessation of breathing (apnoea) during sleep, is a highly prevalent disease associated with significant increase of morbidity and mortality. Obstructive sleep apnoea (OSA) in particular, where airflow reduction and cessation are caused mainly by an obstruction in the upper airway, is predominantly a disorder in men,⁷⁴ and for this reason the vast majority of the literature in the field has often neglected the different pathophysiology, clinical manifestations and consequences of such sleep disorder in women. This is clinically relevant as women with undiagnosed severe OSA have a 3.5-fold increase in the incidence of cardiovascular mortality after adjusting for confounders.⁷⁵ From a pathophysiological standpoint, women, compared to men are characterized by different hormonal fluctuations during their life span.⁷⁶ In particular, progesterone and estrogen levels tend to rise in adolescence and decline in menopause whilst varying significantly within the menstrual cycle and during pregnancy. Progesterone is a ventilatory drive stimulant and appears to increase the activity of the genioglossus muscle therefore dilating the upper airway.⁷⁷ Oestrogens also seem to be protective against OSA: animal studies indicate that oestradiol can reduce the oxidative stress brought on by prolonged intermittent hypoxia during OSA.⁷⁸ Furthermore, there are sex-specific differences related to anatomy: the different body fat distribution and the relatively shorter pharyngeal length compared to men can favor a reduced upper airway collapsibility, better muscle compensation and lower respiratory arousal thresholds.⁷⁹ These features can explain the relatively shorter duration of obstructive events in women, characterized by more hypopnoea events and fewer apnoea events and less oxygen desaturation and the predominance of REM-related OSA. Regarding clinical manifestations, while male patients with sleep disordered breathing complain of the typical OSA symptoms like snoring, unrefreshing sleep and daytime sleepiness, female patients tend to report symptoms like fatigue, poor energy levels and mood disturbances.^{80–81} This can at least in part explain why OSA can be under diagnosed and wrongly classified in women with inevitable consequences on treatment and outcomes. Pregnancy deserves to be mentioned as it is a sex-specific physiological event that can predispose to sleep breathing disorders

due to hormonal changes, weight gain and changes in ventilatory control and upper airway anatomy.⁸² When diagnosed, OSA in pregnancy can have an impact on maternal outcomes such as preterm birth.⁸³ OSA has also been associated with gestational diabetes and increased risk of hypertensive disorders of pregnancy.⁸² OSA tends to be more prevalent in post-menopausal compared to pre-menopausal women.⁸⁴ This is not only due to age but possibly also to changes in the quantity and distribution of body fat, differences in endogenous sex hormones, such as estrogen and progesterone, and pharyngeal dilating muscle activity. Hormone replacement therapy is supposed to play a role in improving OSA severity, however, interventional randomized controlled studies are scarce and the results of such trials taken together do not allow to prescribe hormonal treatment to treat OSA in menopausal women.⁸⁵

Bronchiectasis in Women

Bronchiectasis is the third most common airway disease following asthma and COPD, with a prevalence estimated at 250–500:100,000, or 0.25–0.5% of the population.^{86–89} The prevalence of bronchiectasis in various reports is higher in women compared to men, with women comprising 55–70% of individuals with bronchiectasis in Western countries.^{86,90,91} Surprisingly, women dominance has been reported even in adults with Primary Ciliary Dyskinesia (PCD), a genetic disease of autosomal-recessive inheritance that results in bronchiectasis.⁹² Women predominance is not universal, however. In reports from India, bronchiectasis was more prevalent in men (56.9% men in the Indian bronchiectasis registry),^{93,94} and similarly, men dominance is reported in Eastern European countries.⁹⁵ In children with bronchiectasis, the prevalence of bronchiectasis was reported to be slightly higher in boys than in girls in indigenous populations.⁹⁶ Other than prevalence difference, women with bronchiectasis have been found to have milder severity, but to be more frequently infected with *Pseudomonas aeruginosa* (PA), and report a worse quality of life compared to men when adjusted to age and bronchiectasis severity. Women were found more likely than men to receive guideline-recommended bronchiectasis care including aetiological testing, pulmonary rehabilitation and airway clearance instructions, and long-term antibiotics.⁹⁵

Sex imbalance in bronchiectasis prevalence may stem from different aetiologies, as well as structural, hormonal, chromosomal, and behavioral influences. In a European bronchiectasis registry (EMBARC) analysis, COPD and smoking were reported more often in men with bronchiectasis, while asthma and connective tissue diseases were more prevalent in women with bronchiectasis.⁹⁵ The combination of COPD and bronchiectasis has been established as an independent predictor of severity^{97–100} which may explain the greater severity in men. Differences in chest structure between men and women have been implicated in the elevated prevalence of non-tuberculous mycobacteria pulmonary disease (NTM-pd) among women,¹⁰¹ where middle-lobe predominant bronchiectasis is more common in women¹⁰² (Fig. 1). Hormonal differences – mainly the effect of Estrogen – have been implicated, as estrogen was reported to increase PA alginate production and mucoidity.¹⁰³ In women with cystic fibrosis (CF), pulmonary exacerbations were reported to be more frequent during the follicular phase of the reproductive cycle and to coincide with elevated blood estrogen levels. Furthermore, data from the Irish CF registry showed that oral contraceptive use reduced pulmonary exacerbations.¹⁰³ Hormonal responses thought to affect sex differences in CF may not be equally influential in bronchiectasis, with a mean age of above 60, when menopause is accompanied by decreases in levels of female sex hormones to levels below those in males. Immune responses may




Fig. 1. Summary of vascular lung diseases highlighting differentiating factors specific to women. *Abbreviations:* CTEPH: chronic thromboembolic pulmonary hypertension; PAH: pulmonary arterial hypertension; VTE: venous thromboembolism.

Table 1
Differences in Epidemiology and Symptoms Between Men and Women.

	Disease prevalence	Diagnosis	Symptoms	Exacerbation frequency	Hormonal influence on disease severity
COPD	Higher in males but increasing in women (Men 9–14%, women 6–8%) ³	Frequently delayed; under-diagnosis	Women present with more dyspnea and less sputum	Increased	Unknown
Asthma	Children: higher in males Adults: higher in women (general prevalence 1–18%, 2/3 women in adulthood) ¹¹²	No differences reported	More symptoms Worse quality of life	Increased	Estrogens: worse Testosterone: protective
Bronchiectasis	Higher in women (total 0.25–0.5 ½ to 2/3 of women) ^{86–89} equal in CF bronchiectasis	No differences reported	More dyspnea	No differences reported	Unknown
ILD	Lower in women (20–45% of cases), ^{36–41} except for LAM and autoimmune related ILD	No differences reported	No differences	No differences reported	Estrogens in LAM
OSA	Lower in women (Men 43%, women 28% between 50 and 70 yo) ¹¹³	Underdiagnosis	Less typical symptoms	NA	Estrogens and progesterone, protective

be different in women and men, increasing inflammatory responses in women since the time of puberty.¹⁰⁴ Behavioral differences may include differences in recognition of symptoms and turning to medical care for the diagnosis, as well as in adherence to treatment recommendations.⁹⁵

Some women- specific issues may be encountered more frequently in women with bronchiectasis. Women with bronchiectasis are more frequently affected than men by stress urinary incontinence,^{105–107} which should be actively sought and treated. Young women (and men) with bronchiectasis secondary to PCD (primary ciliary dyskinesia) were reported to have increased rates of subfertility¹⁰⁸ and ectopic pregnancies, with contradicting findings between studies.¹⁰⁹ Data on pregnancy outcomes in young women with bronchiectasis are scarce. A single-center retrospective study has found a lower rate of live births (0.77 ± 0.3 vs. 0.9 ± 18 , $p=0.02$), and a trend toward increased rate of low birth weight and neonatal malformations among women with bronchiectasis compared to controls.¹¹⁰ The European Respiratory Society/Thoracic Society of Australia and New Zealand (ERS/TSANZ) Task Force Statement on the management of reproduction and pregnancy in women with airways diseases recommends attention

to nutritional needs and maintaining airway clearance throughout pregnancy.¹¹¹ Table 1 summarized differences in epidemiology and symptoms between men and women.

Vascular Diseases in Women

Pulmonary Embolism (PE)

PE is globally the third most frequent acute cardiovascular disease following myocardial infarction and stroke.^{114,115} In women, the incidence of VTE is higher during the reproductive age, which can be explained by pregnancy and hormonal treatments. However, from the age of 45 onwards, the incidence is higher in men.¹¹⁶

Optimal anticoagulant treatment duration depends on whether the risk factor is persistent, transient, major, or minor.¹¹⁷ For patients with unprovoked VTE (venous thromboembolism), the recommendation is to undergo long-term anticoagulant treatment.^{114,115,118} In this population, scores have been developed to safely discontinue anticoagulant treatment, where the female sex is considered a protective factor due to its lower incidence of recurrent VTE.^{119–121}




Fig. 2. Highlights of the characteristics of some respiratory diseases in women. *Abbreviations:* COPD, chronic obstructive pulmonary disease; OSA, obstructive lung disease; ILD, interstitial lung disease; AI, autoimmune; PAH, pulmonary arterial hypertension; QoL, quality of life.

Occult cancer is detected in 5% of patients within 1-year after unprovoked VTE, and the risk for females is lower than for males.¹²² Furthermore, females showed more heterogeneity in cancer locations, with the most frequent being colorectal, breast, uterine, hematologic, and pancreatic cancers.¹²³

Hormonal treatment may be continued during anticoagulant treatment in women who had experienced VTE to prevent pregnancy and mitigate the risk of abnormal uterine bleeding.¹²⁴

Thrombophilia testing is not recommended in patients with VTE, and only should be performed if the results may modify the management of the patient in terms of type, dosage, or duration of anticoagulant therapy or counseling on oral contraception or prophylactic measures during pregnancy for female first-degree relatives.¹²⁴

Pulmonary Arterial Hypertension (PAH)

Registries of PAH have reported a higher incidence in women, with a female-to-male ratio ranging from 1.4:1 to 4.1:1.^{125,126} This difference between men and women is even greater in younger patients and tends to equalize after the age of 65.¹²⁶ Female dominance has been associated with hormonal changes occurring during menopause.¹²⁷ However, registries have shown that women with

PAH have better survival rates than men. This difference between sexes in PAH has been referred to as the “estrogen paradox,” where although women have a higher susceptibility, once they develop the disease, they exhibit a better response to treatment and prognosis.^{128–130}

Most of different subgroups of PAH have a similar distribution of sex. Women with connective tissue disease have a higher risk, up to 9 times, than men of developing PH.^{131,132} Up to 12% of women with systemic sclerosis will develop pulmonary hypertension, with this incidence being higher than in men, although survival is better.^{133,134} Other subgroups of PAH present a balanced distribution, with a slight predominance in men in amphetamine-induced PH and PH associated with HIV infection.^{135,136}

A pooled analysis of randomized clinical trials that included 1130 patients with PAH receiving endothelin receptor antagonists or placebo concluded a better treatment response in women, measured by the 6-minute walking test (6MWT).¹³⁷ On the other hand, a sub-analysis evaluating the response to tadalafil found that women had a worse quality of life and covered a shorter distance in the 6MWT.¹³⁸ No differences have been found between sexes in the response to riociguat treatment.¹³⁹ Among patients who required epoprostenol, women have fewer hospitalizations and better survival.¹⁴⁰

When treatment adherence was analyzed, no differences were found between men and women.¹⁴¹

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

CTEPH is an infrequent complication of acute PE, and the diagnosis is based on findings obtained after at least 3 months of anticoagulation. These findings are mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg with a pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg measured in the right heart catheterization (RHC) and pulmonary vascular resistance (PVR) > 2 , with mismatched perfusion defects on lung scan and specific diagnostic signs for CTEPH seen by multidetector computed tomography pulmonary angiography (CTPA), magnetic resonance imaging (MRI) or conventional pulmonary cineangiography, such as ring-like stenoses, webs/slits and chronic total occlusions.^{142–144} The CTEPH treatment includes a global approach of combinations of pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), and medical therapies.^{143,144} The treatment of choice in these patients is PEA because it is a potentially curative treatment.

An observational study analyzed the incidence of risk factors for CTEPH, which included 23,329 patients with VTE, found that female sex was one of the variables associated with CTEPH.¹⁴⁵ On the other hand, women with CTEPH have better survival,^{146,147} although with more hemodynamic deterioration than men.¹⁴⁸ These findings can be justified by the fact that women undergo PEA less frequently and are classified more often as inoperable patients, especially in centers with a low patient volume.¹⁴⁹ Another factor to consider is that women take longer to be diagnosed with CTEPH and therefore are in a more advanced clinical stage of the disease at the time of diagnosis.¹⁴⁹ In a population-based cohort study, it was observed that there were no differences in survival between men and women undergoing PEA.¹⁵⁰ Fig. 1 summarizes the differences in vascular lung diseases between men and women.

Conclusion

Men and women differ on the presentation and prognosis of respiratory diseases. Although women have been both under represented and under recognized in clinical practice and in studies, there's an increasing recognition of the influence of sex in airway diseases. Women with COPD experience more severe symptoms and exacerbations at younger ages, despite lower tobacco exposure, yet they remain underdiagnosed. In contrast, OSA is also underdiagnosed in women due to atypical symptoms and hormonal influences. Asthma prevalence and severity in women are influenced by hormonal changes, while bronchiectasis is more prevalent in women in Western populations, with unique clinical presentations influenced by hormonal and immune factors. Women are more prone to autoimmune-related ILD and experience delays in receiving treatments like antifibrotic therapy. PAH shows a higher prevalence but a better survival in women. There is a growing need to consider these factors in research and to personalize care and treatment based on sex and adapted to the different stages of a woman's life (Fig. 2).

Generative AI

AI Involvement: some individual components of Fig. 2 were generated with the help of AI and then assembled together to create the finale figure.

Funding

This manuscript has not received any funding.

Conflicts of Interest

LJP received grants from Leo Pharma and MSD and personal fees from Daichii, Rovi, GlaxoSmithKline, BMS and Johnson and Johnson outside the submitted work. No other conflict of interest declared.

MB has received speaker fees from Grifols, Menarini, CSL Behring, GSK, Boehringer Ingelheim, Chiesi and consulting fees from GSK, Novartis, Chiesi, CSL Behring, Chiesi and Boehringer Ingelheim.

MS received grants from GSK, Trudel medical int., and the Tel Aviv league for lung diseases, consulting fees from Astra Zeneca, Boehringer Ingelheim, Dexcel, Kamada, Synchrony medical, Truemed, Vertex, Zambon; speakers fees from Astra Zeneca, Boehringer Ingelheim, GSK, Kamada, Sanofi, Insmed; participation in advisory and DSMB boards- Bonus biotherapeutics, Astra Zeneca, Boehringer Ingelheim.

DA received grants from Boehringer-Ingelheim, Canadian Institute for Health Research, McGill University, and speakers fees and consulting fees from Hoffman La Roche and Boehringer Ingelheim.

MH has received grants or contracts from NIH, Sanofi, Novartis, Nuvaira, Sunovion, Gala Therapeutics, COPD foundation, AstraZeneca, American Lung Association, Boehringer Ingelheim and Biodesix; consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron, Altesa BioPharma Amgen Roche, RS Biotherapeutics, AprexHealth, Genentech; speaker fees or honoraria from Cipla, Chiesi, AstraZeneca Boehringer Ingelheim, GSK, Medscape, integrity NACE, Medwiz.

FS has received grants from GSK and AZ, Honoraria for lectures: GSK, AZ, Chiesi, Sanofi, TEVA, ALK.

MP has received honoraria for lectures: Omron, Neopharmed Consultancy: Idorsia.

References

1. Pinkerton KE, Harbaugh M, Han MK, Jourdan Le Saux C, Van Winkle LS, Martin WJ 2nd, et al. Women and lung disease sex differences and global health disparities. *Am J Respir Crit Care Med*. 2015;192:11–6.
2. World Health Organization. The top 10 causes of death. Newsroom: Fact sheets; 2020. <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> [accessed 31.10.23].
3. Ntritsos G, Franek J, Belbasis L, Christou MA, Markozannes G, Altman P, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis*. 2018;13:1507–14.
4. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. *J Glob Health*. 2015;5:020415.
5. Han MK. Chronic obstructive pulmonary disease in women: a biologically focused review with a systematic search strategy. *Int J Chron Obstruct Pulmon Dis*. 2020;15:711–21.
6. Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. *Int J Chron Obstruct Pulmon Dis*. 2014;9:1145–54.
7. Hardin M, Foreman M, Dransfield MT, Hansel N, Han MK, Cho MH, et al. Sex-specific features of emphysema among current and former smokers with COPD. *Eur Respir J*. 2016;47:104–12.
8. Sørheim IC, Johannessen A, Gulsvik A, Bakke PS, Silverman EK, DeMeo DL. Gender differences in COPD: are women more susceptible to smoking effects than men? *Thorax*. 2010;65:480–5.
9. Martinez CH, Raparla S, Plauschnat CA, Giardino ND, Rogers B, Beresford J, et al. Gender differences in symptoms and care delivery for chronic obstructive pulmonary disease. *J Womens Health (Larchmt)*. 2012;21:1267–74.
10. Scicluna V, Han M. COPD in women: future challenges. *Arch Bronconeumol*. 2023;59:3–4.
11. Ancochea J, Miravittles M, García-Río F, Muñoz L, Sánchez G, Sobradillo V, et al. Underdiagnosis of chronic obstructive pulmonary disease in women: quantification of the problem, determinants and proposed actions. *Arch Bronconeumol*. 2013;49:223–9.
12. Wan ES, Balte P, Schwartz JE, Bhatt SP, Cassano PA, Couper D, et al. Association between preserved ratio impaired spirometry and clinical outcomes in US adults. *JAMA*. 2021;326:2287–98.
13. Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. *Arch Bronconeumol*. 2023;59:232–48.

14. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. *N Engl J Med*. 2018;378:1671–80.
15. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. *N Engl J Med*. 2020;383:35–48.
16. Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. *N Engl J Med*. 2023;389:205–14.
17. Kumbhare S, Pleasants R, Ohar JA, Strange C. Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States. *Ann Am Thorac Soc*. 2016;13:803–10.
18. Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. *BMC Pulm Med*. 2013;26:11.
19. Schleich FN, Zanella D, Stefanuto PH, Bessonov K, Smolinska A, Dallinga JW, et al. Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma. *Am J Respir Crit Care Med*. 2019;200:444–53.
20. Moore WC, Bleeker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart Lung, and Blood Institute's Severe Asthma Research Program 1. *J Allergy Clin Immunol*. 2007;119:405–13.
21. Halder P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes 1. *Am J Respir Crit Care Med*. 2008;178:218–24.
22. Schleich FN, Chevremont A, Paulus V, Henket M, Manise M, Seidel L, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. *Eur Respir J*. 2014;44:97–108.
23. Gibbs CJ, Coutts II, Lock R, Finnegan OC, White RJ. Premenstrual exacerbation of asthma. *Thorax*. 1984;39:833–6.
24. Eliasson O, Scherzer HH, DeGraff AC. Morbidity in asthma in relation to the menstrual cycle. *J Allergy Clin Immunol*. 1986;77:87–94.
25. Oguzulgen IK, Turkas H, Erbas D. Airway inflammation in premenstrual asthma. *J Asthma*. 2002;39:517–22.
26. Yung JA, Fuseini H, Newcomb DC. Hormones, sex, and asthma. *Ann Allergy Asthma Immunol*. 2018;120:488–94.
27. Ambhore NS, Kalidhindi RSR, Loganathan J, Sathish V. Role of differential estrogen receptor activation in airway hyperreactivity and remodeling in a murine model of asthma. *Am J Respir Cell Mol Biol*. 2019;61:469–80.
28. Kwon HL, Triche EW, Belanger K, Bracken MB. The epidemiology of asthma during pregnancy: prevalence, diagnosis, and symptoms. *Immunol Allergy Clin North Am*. 2006;26:29–62.
29. Schatz M, Dombrowski MP, Wise R, Thom EA, Landon M, Mabie W, et al. Asthma morbidity during pregnancy can be predicted by severity classification. *J Allergy Clin Immunol*. 2003;112:283–8.
30. Barr RG, Wentowski CC, Grodstein F, Somers SC, Stampfer MJ, Schwartz J, et al. Prospective study of postmenopausal hormone use and newly diagnosed asthma and chronic obstructive pulmonary disease. *Arch Intern Med*. 2004;164:379–86.
31. Bulkhi AA, Shepard KV, Casale TB, Cardet JC. Elevated testosterone is associated with decreased likelihood of current asthma regardless of sex. *J Allergy Clin Immunol Pract*. 2020;8:3029–35.
32. Hunninghake GM, Soto-Quirós ME, Avila L, Kim HP, Lasky-Su J, Rafaels N, et al. TSLP polymorphisms are associated with asthma in a sex-specific fashion. *Allergy*. 2010;65:1566–75.
33. Loisel DA, Tan Z, Tisler CJ, Evans MD, Gangnon RE, Jackson DJ, et al. IFNG genotype and sex interact to influence the risk of childhood asthma. *J Allergy Clin Immunol*. 2011;128:524–31.
34. Patel R, Solatikia F, Zhang H, Wolde A, Kadalayil L, Karmaus W, et al. Sex-specific associations of asthma acquisition with changes in DNA methylation during adolescence. *Clin Exp Allergy*. 2021;51:318–28.
35. Moscato G, Apfelbacher C, Brockow K, Eberle C, Genuneit J, Mortz CG, et al. Gender and occupational allergy: report from the task force of the EAACI Environmental and Occupational Allergy Interest Group. *Allergy*. 2020;75:2753–63.
36. Hopkins RB, Burke N, Fell C, Dion G, Kolb M. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. *Eur Respir J*. 2016;48:187–95.
37. Raghu G, Chen S-Y, Hou Q, Yeh W-S, Collard HR. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. *Eur Respir J*. 2016;48:179–86.
38. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. *Lancet Respir Med*. 2014;2:566–72.
39. Strongman H, Kausar I, Maher TM. Incidence prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. *Adv Ther*. 2018;35:724–36.
40. Tarride JE, Hopkins RB, Burke N, Guertin JR, O'Reilly D, Fell CD, et al. Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. *Clinicoecon Outcomes Res*. 2018;10:127–37.
41. Mooney J, Chang E, Lalla D, Papayan E, Raimundo K, Reddy SR, et al. Potential delays in diagnosis of idiopathic pulmonary fibrosis in medicare beneficiaries. *Ann Am Thorac Soc*. 2019;16:393–6.
42. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. *Clin Chest Med*. 2004;25:549–59, vii.
43. Chartrand S, Lee JS, Swigris JJ, Stanchev L, Fischer A. Clinical characteristics and natural history of autoimmune forms of interstitial lung disease: a single-center experience. *Lung*. 2019;197:709–13.
44. Gharaee-Kermani M, Hatano K, Nozaki Y, Phan SH. Gender-based differences in bleomycin-induced pulmonary fibrosis. *Am J Pathol*. 2005;166:1593–606.
45. Voltz JW, Card JW, Carey MA, Degraff LM, Ferguson CD, Flake GP, et al. Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. *Am J Respir Cell Mol Biol*. 2008;39:45–52.
46. Guler SA, Machahua C, Geiser TK, Kocher G, Marti TM, Tan B, et al. Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study. *Respir Res*. 2022;23:149.
47. Svendsen TL, Viskum K, Hansborg N, Thorpe SM, Nielsen NC. Pulmonary lymphangioleiomyomatosis: a case of progesterone receptor positive lymphangioleiomyomatosis treated with medroxyprogesterone, oophorectomy and tamoxifen. *Br J Dis Chest*. 1984;78:264–71.
48. Yockey CC, Riepe RE, Ryan K. Pulmonary lymphangioleiomyomatosis complicated by pregnancy. *Kans Med*. 1986;87:277–8, 93.
49. Eliasson AH, Phillips YY, Tenholder MF. Treatment of lymphangioleiomyomatosis. A meta-analysis. *Chest*. 1989;96:1352–5.
50. Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. *Thorax*. 2000;55:1052–7.
51. Borie R, Renzoni E. Pulmonary fibrosis associated with telomere-related gene mutations: a complex inheritance. *Respirology*. 2021;26:1098–100.
52. Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. *Blood*. 2009;114:2236–43.
53. Diaz de Leon A, Cronkrite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. *PLOS ONE*. 2010;5, e10680.
54. Cronkrite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2008;178:729–37.
55. Johnson J, Greaves L, Repta R. Better science with sex and gender. A primer for health research. Vancouver: Library and Archives Canada Cataloguing in Publication; 2007.
56. Phillips SP. Defining and measuring gender: a social determinant of health whose time has come. *Int J Equity Health*. 2005;4:11.
57. Organization WH. Gender, women, and the tobacco epidemic 2010 [cited 14 Dec 2023]. Available from: <https://www.who.int/publications/i/item/9789240004849>.
58. Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. *Am J Respir Crit Care Med*. 1994;150:670–5.
59. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 1997;155:242–8.
60. Brigham E, Allbright K, Harris D. Health disparities in environmental and occupational lung disease. *Clin Chest Med*. 2020;41:623–39.
61. Poinen-Rughooputh S, Rughooputh MS, Guo Y, Lai H, Sun W, Chen W. Sex-related differences in the risk of silicosis among Chinese pottery workers: a cohort study. *J Occup Environ Med*. 2021;63:74–9.
62. Fazzo L, Cernigliaro A, De Santis M, Quattrone G, Bruno C, Zona A, et al. Occupational cohort study of asbestos-cement workers in a contaminated site in Sicily (Italy). *Epidemiol Prev*. 2020;44:137–44.
63. Blanc PD, Eisner MD, Balmes JR, Trupin L, Yelin EH, Katz PP. Exposure to vapors, gas, dust, or fumes: assessment by a single survey item compared to a detailed exposure battery and a job exposure matrix. *Am J Ind Med*. 2005;48:110–7.
64. Ferrara G, Arnheim-Dahlström L, Bartley K, Janson C, Kirchgässler KU, Levine A, et al. Epidemiology of pulmonary fibrosis: a cohort study using healthcare data in Sweden. *Pulm Ther*. 2019;5:55–68.
65. Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. *Respirology*. 2014;19:493–500.
66. Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. *Chest*. 2014;146:422–36.
67. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multi-dimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med*. 2012;156:684–91.
68. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, et al. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. *Respir Med*. 2017;127:51–6.
69. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. *CHEST J*. 2014;145:723–8.
70. Wälscher J, Witt S, Schwarzkopf L, Kreuter M. Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment – a German claims data analysis. *Respir Res*. 2020;21:73.
71. Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH. Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. *Ann Am Thorac Soc*. 2021;18:1121–8.
72. Assayag D, Garlick K, Johansson KA, Fell CD, Kolb M, Cox G, et al. Treatment initiation in patients with interstitial lung disease in Canada. *Ann Am Thorac Soc*. 2021;18:1661–8.

73. Sesé L, Nunes H, Cottin V, Israel-Biet D, Crestani B, Guillot-Dudoret S, et al. Gender differences in idiopathic pulmonary fibrosis: are men and women equal? *Front Med (Lausanne)*. 2021;8:713698.
74. Garvey JF, Pengo MF, Drakatos P, Kent BD. Epidemiological aspects of obstructive sleep apnea. *J Thorac Dis*. 2015;7:920–9.
75. Campos-Rodríguez F, et al. Role of sleep apnea and continuous positive airway pressure therapy in the incidence of stroke or coronary heart disease in women. *Am J Respir Crit Care Med*. 2014;189:1544–50.
76. Pengo MF, Won CH, Bourjeily G. Sleep in women across the life span. *Chest*. 2018;154:196–206.
77. Popovic RM, White DP. Upper airway muscle activity in normal women: influence of hormonal status. *J Appl Physiol*. 1998;84:1055–62.
78. Laouafa S, Ribon-Demars A, Marcouiller F. Estradiol protects against cardiorespiratory dysfunction and oxidative stress in intermittent hypoxia. *Sleep*. 2017;40(8).
79. Sands SA, Alex RM, Mann D, Vena D, Terrill PI, Gell LK, et al. Pathophysiology underlying demographic and obesity determinants of sleep apnea severity. *Ann Am Thorac Soc*. 2023;20:440–9.
80. Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. *Sleep*. 1997;20:705–6.
81. Redline S, Kump K, Tishler PV, Browner I, Ferrette V. Gender differences in sleep disordered breathing in a community-based sample. *Am J Respir Crit Care Med*. 1994;149:722–6.
82. Pengo MF, Rossi GP, Steier J. Obstructive sleep apnea, gestational hypertension and preeclampsia: a review of the literature. *Curr Opin Pulm Med*. 2014;20:588–94.
83. Bourjeily G, Danilack VA, Bublit MH. Obstructive sleep apnea in pregnancy is associated with adverse maternal outcomes: a national cohort. *Sleep Med*. 2017;38:50–7.
84. Perger E, Mattaliano P, Lombardi C. Menopause and sleep apnea. *Maturitas*. 2019;124:35–8.
85. Lindberg E, Bonsignore MR, Polo-Kantola P. Role of menopause and hormone replacement therapy in sleep-disordered breathing. *Sleep Med Rev*. 2020;49:101225.
86. Quint JK, Millet ERC, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. *Eur Respir J*. 2016;47:186–93.
87. Snell N, Gibson J, Jarrold I, Quint JK. Epidemiology of bronchiectasis in the UK: findings from the British lung foundation's "Respiratory health of the nation" project. *Respir Med*. 2019;158:21–3.
88. Choi H, Yang B, Nam H, Kyoung D-S, Sim YS, Park HY, et al. Population-based prevalence of bronchiectasis and associated comorbidities in South Korea. *Eur Respir J*. 2019;54, 1900194.
89. Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. *Chron Respir Dis*. 2017;14:377–84.
90. Chalmers JD, Polverino E, Crichton ML, Ringshausen FC, De Soyza A, Vendrell M, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). *Lancet Respir Med*. 2023;11:637–49.
91. Aksamit TR, O'Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. *Chest*. 2017;151:982–92.
92. Shoemark A, Polverino E, Blasi F, Ringshausen FC, De Soyza A, Vendrell M, et al. Characteristics and outcomes of adults with primary ciliary dyskinesia (PCD): an EMBARC/BEAT-PCD analysis Respiratory infections and bronchiectasis. *Eur Respir Soc*. 2021:PA2062.
93. Dhar R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnakar R, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. *Lancet Glob Health*. 2019;7:e1269–79.
94. Dhar R, Singh S, Talwar D, Murali Mohan BV, Tripathi SK, Swarnakar R, et al. Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry. *Eur Respir J*. 2023;61:2200611.
95. Finch S, Polverino E, Blasi F, Ringshausen F, De Soyza A, Vendrell M, et al. Sex differences in bronchiectasis patient characteristics: an analysis of the EMBARC cohort, epidemiology. *Eur Respir Soc*. 2018:PA2282.
96. Singleton RJ, Valery PC, Morris P, Byrnes CA, Grimwood K, Redding G, et al. Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. *Pediatr Pulmonol*. 2014;49:189–200.
97. Martínez-García MÁ, Soler-Cataluña JJ, Donat Sanz Y, Catalán Serra P, Agramunt Lerma M, Ballestín Vicente J, et al. Factors associated with bronchiectasis in patients with COPD. *Chest*. 2011;140:1130–7.
98. Huang JT-J, Cant E, Keir HR, Barton AK, Kuzmanova E, Shuttleworth M, et al. Endotyping Chronic Obstructive Pulmonary Disease Bronchiectasis, and the "Chronic Obstructive Pulmonary Disease-Bronchiectasis Association". *Am J Respir Crit Care Med*. 2022;206:417–26.
99. Gatheral T, Kumar N, Sansom B, Lai D, Nair A, Vlahos J, et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. *COPD*. 2014;11:605–14.
100. Shi L, Wei F, Ma T, Zhou W, Li M, Wan Y. Impact of radiographic bronchiectasis in COPD. *Respir Care*. 2020;65:1571–3.
101. Kumar K, Loebinger MR. Nontuberculous mycobacterial pulmonary disease: clinical epidemiologic features, risk factors, and diagnosis: the nontuberculous mycobacterial series. *Chest*. 2022;161:637–46.
102. McDonnell MJ, Ahmed M, Das J, O'Mahony M, Breen D, O'Regan A, et al. Patterns of disease in patients with middle-lobe predominant bronchiectasis. *Respiration*. 2017;20;93:406–14.
103. Chotirmall SH, Smith SG, Gunaratnam C, Cosgrove S, Dimitrov BD, O'Neill SJ, et al. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. *N Engl J Med*. 2012;366:1978–86.
104. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*. 2016;16:626–38.
105. Prys-Picard CO, Niven R. Urinary incontinence in patients with bronchiectasis. *Eur Respir J*. 2006;27:866–7.
106. Rees J, Tedd H, De Soyza A. Managing urinary incontinence in adults with bronchiectasis. *Br J Nurs*. 2013;22:S15–6. S18.
107. Duignan N, McDonnell MJ, Mokoka MC, Rutherford RM. High prevalence of stress urinary incontinence in adult patients with bronchiectasis. *Ir Med J*. 2016;109:440.
108. Afzelius BA, Eliasson R. Male and female infertility problems in the immotile-cilia syndrome. *Eur J Respir Dis Suppl*. 1983;127:144–7.
109. Raidt J, Werner C, Menchen T, Dougherty GW, Olbrich H, Loges NT, et al. Ciliary function and motor protein composition of human fallopian tubes. *Hum Reprod*. 2015;30:2871–80.
110. Börekçi Ş, Kubat B, Senkardesler G, Musellim B. Maternal and fetal problems in patients with non-cystic fibrosis bronchiectasis during pregnancy. *Turk Thorac J*. 2021;22:297–300.
111. Middleton PG, Gade EJ, Aguilera C, MacKillop L, Button BM, Coleman C, et al. ERS/TSANZ Task Force Statement on the management of acute pulmonary embolism in women with airways diseases. *Eur Respir J*. 2020;55: 1901208.
112. Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. *Eur Respir Rev*. 2021;30:210067.
113. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol*. 2013;177:1006–14.
114. Konstantinides SV, Meyer G, Bueno H, Galié N, Gibbs JSR, Agno W, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). *Eur Heart J*. 2020;41:543–603.
115. Konstantinides SV, Meyer G, Galié N, Simon R, Gibbs J, Aboyans V, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Respir J*. 2019;41:543–603.
116. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med*. 1998;158:585–93.
117. Kearon C, Agno W, Cannegieter SC, Cosmi B, Geersing CJ, Kyrle PA. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. *J Thromb Haemost*. 2016;14:1480–3.
118. Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing CJ, et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. *Chest*. 2021;160:2247–59.
119. Cosmi B. Management of idiopathic venous thromboembolism. *Expert Rev Cardiovasc Ther*. 2016;14:1371–84.
120. Kyrle PA, Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. *Thromb Haemost*. 2012;108:1061–4.
121. Streiff MB. Predicting the risk of recurrent venous thromboembolism (VTE). *J Thromb Thrombolysis*. 2015;39:353–66.
122. Jara-Palomares L, Otero R, Jiménez D, Carrier M, Tzoran I, Brenner B, et al. Development of a risk prediction score for occult cancer in patients with VTE. *Chest*. 2017;151:564–71.
123. Jara-Palomares L, Otero R, Jiménez D, Praena-Fernández JM, Rivas A, Font C, et al. Sex differences in patients with occult cancer after venous thromboembolism. *Clin Appl Thromb Hemost*. 2018;24:489–95.
124. Klok FA, Agno W, Ay C, Bäck M, Barco S, Bertolotti L, et al. Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. *Eur Heart J*. 2022;43:183–9.
125. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. *Chest*. 2010;137:376–87.
126. Hoepfer MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. *Int J Cardiol*. 2013;168:871–80.
127. Ventetuolo CE, Praetgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM. Sex and haemodynamics in pulmonary arterial hypertension. *Eur Respir J*. 2014;43:523–30.
128. Humbert M, Sitbon O, Yaici A, Montani D, O'Callaghan DS, Jaïs X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. *Eur Respir J*. 2010;36:549–55.
129. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al. Anti-coagulation and survival in pulmonary arterial hypertension: results from the Comparative Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). *Circulation*. 2014;129:57–65.

130. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation*. 2010;122:164–72.
131. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. *Chest*. 2010;138:1383–94.
132. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. *Am J Respir Crit Care Med*. 2006;173:1023–30.
133. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. *Ann Rheum Dis*. 2003;62:1088–93.
134. Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. *Chest*. 2014;146:1494–504.
135. Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JL, Jorden M, et al. Features and outcomes of methamphetamine-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2018;197:788–800.
136. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. *Am J Respir Crit Care Med*. 2008;177:108–13.
137. Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. *Chest*. 2012;141:20–6.
138. Mathai SC, Hassoun PM, Puhon MA, Zhou Y, Wise RA. Sex differences in response to tadalafil in pulmonary arterial hypertension. *Chest*. 2015;147:188–97.
139. Ghofrani H-A, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. *N Engl J Med*. 2013;369:330–40.
140. Frantz RP, Schilz RJ, Chakinala MM, Badesch DB, Frost AE, McLaughlin VV, et al. Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study. *Chest*. 2015;147:484–94.
141. Kjellström B, Sandqvist A, Hjalmarsson C, Nisell M, Näsman P, Ivarsson B. Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. *ERJ Open Res*. 2020;6:1–10.
142. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. ERS statement on chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2021;57.
143. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J*. 2023;61:2200879.
144. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2022;43:3618–731.
145. Martinez C, Wallenhorst C, Teal S, Cohen AT, Peacock AJ. Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England. *Pulm Circ*. 2018;8, 2045894018791358.
146. Chen TX, Pudasaini B, Guo J, Gong SG, Jiang R, Wang L, et al. Sex-specific cardiopulmonary exercise testing indices to estimate the severity of inoperable chronic thromboembolic pulmonary hypertension. *Int J Chron Obstruct Pulmon Dis*. 2018;13:385–97.
147. Escribano-Subias P, Blanco I, López-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. *Eur Respir J*. 2012;40:596–603.
148. Yang YL, Yu YZ, Yuan P, Gong SG, Wang CY, Li Y, et al. Sex differences of hemodynamics during acute vasoreactivity testing to predict the outcomes of chronic thromboembolic pulmonary hypertension. *Clin Respir J*. 2020;14:611–21.
149. Barco S, Klok FA, Konstantinides SV, Dartevielle P, Fadel E, Jenkins D, et al. Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. *J Thromb Haemost*. 2020;18:151–61.
150. Kallonen J, Korsholm K, Bredin F, Corbascio M, Andersen MJ, Ilkjær LB, et al. Sex and survival following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a Scandinavian observational cohort study. *Pulm Circ*. 2021;11, 20458940211056014.